IP Library Granted Patent US 9,567,404
Granted Patent B2
US 9,567,404 · App. 15/203,040 · Granted Feb 14, 2017

Anti-vasa antibodies, and methods of production and use thereof

Inventors: David T. Weaver (Newton, MA); Bo Zhang (Lynnfield, MA)
Assignee: OvaScience, Inc.
C07K16/40G01N33/573C07K2317/14C07K2317/51C07K2317/515C07K2317/52C07K2317/56C07K2317/565C07K2317/622G01N2333/914
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,567,404
App. No.
15/203,040
Granted
Feb 14, 2017
Kind
B2
Abstract

Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

Claims (14)

1. A cell transformed with a nucleic acid molecule encoding a heavy chain or light chain of an antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain,

a) wherein the variable region of said light chain comprises:

(i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 83-88;

(ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-95; and

(iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-104; and

b) wherein the variable region of said heavy chain comprises:

(i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112;

(ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 113-121; and

(iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 122-131.

2. The cell of claim 1 , wherein said nucleic acid molecule is selected from the group consisting of a cloning vector, an expression vector, a heterologous recombination vector, and a viral integration vector.

3. The cell of claim 1 , wherein said cell is a mammalian cell.

4. The cell of claim 3 , wherein said cell is a rodent cell.

5. The cell of claim 3 , wherein said cell is a Chinese Hamster Ovary (CHO) cell.

6. The cell of claim 3 , wherein said cell is a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2016
From: WEAVER, DAVID T.; ZHANG, BO
To: OVASCIENCE, INC.
Reel/Frame 039184/0881 →
Continuity (4)
Continuation 14856380 · Sep 16, 2015
Provisional Application 62089054 · Dec 8, 2014
Provisional Application 62051130 · Sep 16, 2014
Related Publication 20160311929A1 · Oct 27, 2016